스타틴계 고지혈증치료제의 골절치료효과에 대한 분석 (Analysis on Statins for The Treatment of Bone Fracture)

서지정보

· 발행기관 : 대한약학회
· 수록지 정보 : 약 학 회 지 / 53권 / 4호 / 206 ~ 216페이지
· 저자명 : 최병철

초록

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Statins) are potent inhibitors of cholesterol biosynthesis.
Cholesterol-lowering therapy using statins significantly reduces the risk of coronary heart disease. Various discovery
of statins as bone anabolic agents has spurred a great deal of interest among both basic and clinical bone researchers.
In-vitro and some animal studies suggest that statins increase the bone mass by enhancing bone morphogenetic protein-
2 (BMP-2)-mediated osteoblast expression. Clinical and animal test results of statins focusing on the prevention and treatment
of bone fractures was collected. Three independent literature searches were performed by using from January 1, 2002
to September 2008 for clinical and animal test results. Search term included statins, HMG-CoA reductase inhibitors, pleiotropic
effects, fracture, osteoporosis and clinical and animal test. No consensus has been reached whether clinical use of
statins has beneficial effects on bone health, partly due to lower statin concentrations because of first-pass metabolism by
the liver. Experimental use of statins as stimulators of bone formation suggests that they may have widespread applicability
in the field of orthopaedics. With their combined effects on osteoblasts and osteoclasts, statins have the potential to enhance
resorption of synthetic materials and improve bone ingrowth. In conclusion, The use of statins in the prevention and treatment
of bone fractures requires further study. But observational studies suggest that statins for decreasing bone fractures
including osteoporosis have to be considered local direct administration like transdermal or subcutaneous type over oral
adminstration.

영어초록

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Statins) are potent inhibitors of cholesterol biosynthesis.
Cholesterol-lowering therapy using statins significantly reduces the risk of coronary heart disease. Various discovery
of statins as bone anabolic agents has spurred a great deal of interest among both basic and clinical bone researchers.
In-vitro and some animal studies suggest that statins increase the bone mass by enhancing bone morphogenetic protein-
2 (BMP-2)-mediated osteoblast expression. Clinical and animal test results of statins focusing on the prevention and treatment
of bone fractures was collected. Three independent literature searches were performed by using from January 1, 2002
to September 2008 for clinical and animal test results. Search term included statins, HMG-CoA reductase inhibitors, pleiotropic
effects, fracture, osteoporosis and clinical and animal test. No consensus has been reached whether clinical use of
statins has beneficial effects on bone health, partly due to lower statin concentrations because of first-pass metabolism by
the liver. Experimental use of statins as stimulators of bone formation suggests that they may have widespread applicability
in the field of orthopaedics. With their combined effects on osteoblasts and osteoclasts, statins have the potential to enhance
resorption of synthetic materials and improve bone ingrowth. In conclusion, The use of statins in the prevention and treatment
of bone fractures requires further study. But observational studies suggest that statins for decreasing bone fractures
including osteoporosis have to be considered local direct administration like transdermal or subcutaneous type over oral
adminstration.

참고자료

· 없음